Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.

@article{Spiridonidis1998PhaseIS,
  title={Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.},
  author={C Harris Spiridonidis and Leslie Rogers Laufman and J. J. Jones and Verna A Rhodes and Kris Wallace and Steven J. Nicol},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 12},
  pages={3866-73}
}
PURPOSE To determine the maximum-tolerated dose of monthly docetaxel combined with fixed-dose weekly gemcitabine and describe the dose-limiting toxicities (DLTs) of the combination. PATIENTS AND METHODS Patients with refractory solid tumors were treated with gemcitabine days 1, 8, and 15 every 4 weeks at a fixed dose of 800 mg/m2. Two docetaxel administration schedules were studied, with the drug administered either day 1 or day 15 at doses of 45, 60, 75, and 100 mg/m2 per cycle. RESULTS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Chemotherapy in Non-Small Cell Lung Cancer

Investigational New Drugs • 2000
View 4 Excerpts
Highly Influenced

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis

Cancer research and treatment : official journal of Korean Cancer Association • 2012

Similar Papers

Loading similar papers…